<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810444</url>
  </required_header>
  <id_info>
    <org_study_id>991</org_study_id>
    <secondary_id>2015-003652-52</secondary_id>
    <nct_id>NCT02810444</nct_id>
  </id_info>
  <brief_title>Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID</brief_title>
  <official_title>An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotest</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in&#xD;
      treating patients with Primary Immunodeficiency (PID)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2016</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute serious bacterial infections</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of acute serious bacterial infections (i.e., the mean number of acute serious bacterial infections per subject-year) is less than 1.0 to provide substantial evidence of efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG trough levels (total IgG) before each infusion</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of any infections (number per year)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of nonserious infections (number per year)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of infections</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic treatment (number of days antibiotic treatment received per month</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of time lost from school/work due to infections (number of days per month)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment due to infections (number of days treatment per month)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization (number of days per month overall and due to infection)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever episodes (number of days per year)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health related quality of life Parameters, i.e. Peds QL, EQ-5D</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Primary Immunodeficiency Disease</condition>
  <arm_group>
    <arm_group_label>BT595</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IgG Next Generation (BT595)</intervention_name>
    <arm_group_label>BT595</arm_group_label>
    <other_name>Immune Globulin Intravenous (Human), 10% Liquid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for inclusion:&#xD;
&#xD;
          1. Written informed consent/assent obtained from subjects/subjects' parent(s) or legally&#xD;
             acceptable representative indicating that they understood the purpose of, and&#xD;
             procedures required for the study and are willing to participate in it.&#xD;
&#xD;
          2. Male or female, aged 2 through 75 years, inclusive.&#xD;
&#xD;
          3. Diagnosis of PID with impaired antibody production, ie:&#xD;
&#xD;
             - Diagnosis of common variable immunodeficiency (CVID) as defined by the European&#xD;
             Society for Immunodeficiencies (ESID)/Pan American Group for Immunodeficiency (PAGID)&#xD;
             diagnostic criteria.&#xD;
&#xD;
             Or&#xD;
&#xD;
             - X-linked agammaglobulinaemia (XLA) as defined by ESID/PAGID diagnostic criteria.&#xD;
&#xD;
          4. Established replacement therapy with any immunoglobulin for intravenous administration&#xD;
             (IVIg) reference preparation during the previous 6 months, including documentation of&#xD;
             IgG trough levels.&#xD;
&#xD;
          5. Established replacement therapy with a single IVIg reference preparation for ≥3 months&#xD;
             prior to treatment start with BT595 at a 3 week (Q3W) or 4 week (Q4W) schedule with a&#xD;
             constant IVIg dose that did not change by ±20% of the mean dose, regular dosage&#xD;
             intervals, and at least 1 IgG trough level of ≥5 g/L during the previous 3 months.&#xD;
&#xD;
        Criteria for exclusion:&#xD;
&#xD;
          1. Pregnancy or unreliable contraceptive measures or lactation period (females only).&#xD;
&#xD;
          2. Known intolerance to immunoglobulins or comparable substances (eg, vaccination&#xD;
             reaction).&#xD;
&#xD;
          3. Known intolerance to proteins of human origin or known allergic reactions to&#xD;
             components of the study product.&#xD;
&#xD;
          4. Participation in another clinical study within 30 days before entering the study or&#xD;
             during the study and/or previous participation in this study.&#xD;
&#xD;
          5. Employee or direct relative of an employee of the contract research organization, the&#xD;
             study site, or Biotest.&#xD;
&#xD;
          6. Acquired medical conditions known to cause secondary immune deficiency, such as&#xD;
             chronic lymphatic leukemia, lymphoma, multiple myeloma, as well as protein losing&#xD;
             enteropathies and hypoalbuminemia.&#xD;
&#xD;
          7. Other medical condition, laboratory finding, or physical examination finding that&#xD;
             precludes participation.&#xD;
&#xD;
          8. Recent febrile illness that precludes or delays participation.&#xD;
&#xD;
          9. Active infection and receiving antibiotic therapy for the treatment of this infection&#xD;
             at the time of screening. Note: if the subject was deemed to be a screen failure due&#xD;
             to a nonserious active infection requiring antibiotic therapy, the subject may have&#xD;
             been rescreened after the initial screening.&#xD;
&#xD;
         10. Therapy with systemic steroids or other immunosuppressant drugs at the time of&#xD;
             enrollment (current daily use of corticosteroids, ie, &gt;10 mg prednisone equivalent/day&#xD;
             for &gt;30 days. Intermittent corticosteroid use during the study was allowable, if&#xD;
             medically necessary).&#xD;
&#xD;
         11. History of thrombotic events (including myocardial infarction, cerebral vascular&#xD;
             accident [including stroke], pulmonary embolism, and deep vein thrombosis) within the&#xD;
             6 months before treatment start with BT595 or the presence of significant risk factors&#xD;
             for thrombotic events.&#xD;
&#xD;
         12. Therapy with live-attenuated virus vaccines within 3 months before start of the study.&#xD;
&#xD;
         13. Selective, absolute immunoglobulin A (IgA) deficiency or known antibodies to IgA.&#xD;
&#xD;
         14. Positive diagnosis of hepatitis B or hepatitis C.&#xD;
&#xD;
         15. Positive human immunodeficiency virus (HIV) test.&#xD;
&#xD;
         16. History of drug or alcohol abuse within the 12 months before treatment start with&#xD;
             BT595.&#xD;
&#xD;
         17. Inability or lacking motivation to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gergely Krivan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Egyesitett Szent Istvan es Szent Laszlo Korhaz, Budapest, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site # 0104</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0116</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0103</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0114</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0111</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0106</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0105</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site #0115</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103-2800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site # 0102</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 4902</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 4904</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site #4905</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 3602</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site # 3605</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site #3603</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0702</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 0704</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 3403</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site # 3405</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <disposition_first_submitted>March 1, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>March 1, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 2, 2021</disposition_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

